Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial.

Abstract

OBJECTIVE:

To evaluate the long-term efficacy of etanercept for the management of hidradenitis suppurativa.

METHODS:

Analysis was based on the long-term follow-up (weeks 24-144) of 10 patients enrolled in a prospective open-label phase II study; etanercept was initially administered subcutaneously 50 mg once weekly for 12 weeks in 10 patients. Disease recurrence and the need to restart etanercept were recorded.

RESULTS:

Three patients did not report any disease recurrence. A second course of treatment with etanercept was needed in seven patients. Favourable responses were found in five; two patients failed treatment.

CONCLUSIONS:

The first treatment course achieved long-term disease remission in almost one-third of patients. The remaining needed a second treatment course but even in that case, their disease severity at restart was significantly lower compared with baseline.

• Authors: Aimilia Pelekanou, Theodora Kanni, Athina Savva, Maria Mouktaroudi, Maria Raftogiannis, Antigone Kotsaki, Evangelos J Giamarellos-Bourboulis
• Journal: Experimental dermatology (Exp Dermatol) Vol. 19 Issue 6 Pg. 538-40 (Jun 2010) ISSN: 1600-0625 [Electronic] Denmark
• PMID: 19758320 (Publication Type: Clinical Trial, Phase II, Letter)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Etanercept

Topics

• Adolescent
• Adult
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects, therapeutic use)
• Etanercept
• Female
• Follow-Up Studies
• Hidradenitis Suppurativa (diagnosis, drug therapy, pathology)
• Humans
• Immunoglobulin G (administration & dosage, adverse effects, therapeutic use)
• Male
• Middle Aged
• Receptors, Tumor Necrosis Factor (administration & dosage, therapeutic use)
• Recurrence
• Remission Induction
• Severity of Illness Index
• Treatment Outcome